Search results
Results from the WOW.Com Content Network
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. [ 2 ] [ 3 ] Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado .
Here's the story behind the biotech stock that could be the best way to profit from the discovery of the century: CRISPR-Cas9 gene editing.
Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.
IP5 is a forum of the five largest intellectual property offices in the world. The five patent offices are the US Patent and Trademark Office (USPTO), the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), and the National Intellectual Property Administration (CNIPA formerly SIPO) in China.
The issue date is the data the patent is granted, usually 3.5 years after filling depending on the patent office. Crossing dates and locations fields offer a global vision of a technology in time and space. Assignee: Patent assignees are organizations or individuals - the owners of the patent.
After another solid quarter of progress, the genome-editing company looks forward to a phase 1/2 study for its revolutionary CRISPR medicine.
The delay was attributed by spokesmen for the Patent Office to a combination of a sudden increase in business method patent filings after the 1998 State Street Bank decision, the unfamiliarity of patent examiners with the business and financial arts (e.g., banking, insurance, stock trading etc.), and the issuance of a number of controversial ...